Photo of Edward E. Whang,  MD

Edward E. Whang, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8669
Fax: (617) 739-1728


ewhang1@partners.org

Edward E. Whang, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Surgery, Harvard Medical School
  • Assistant Professor, Surgery, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research focuses on 1) pancreatic cancer and 2) intestinal regeneration. We are characterizing factors modulating invasiveness and metastatic potential of pancreatic cancers. Tissue arrays containing resected human pancreatic cancers and a corresponding clinical outcomes database are being constructed to evaluate the clinical importance of specific factors that have been identified using in vitro and in vivo model systems. In addition, we are characterizing the mechanisms of action of intestinal epithelium-specific growth factors and the biology of tissue-engineered intestine.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Pastrana Del Valle J, Mahvi DA, Fairweather M, Wang J, Clancy TE, Ashley SW, Urman RD, Whang EE, Gold JS. Associations of gender, race, and ethnicity with disparities in short-term adverse outcomes after pancreatic resection for cancer. J Surg Oncol 2021. PubMed
  • Pastrana Del Valle J, Mahvi DA, Fairweather M, Wang J, Clancy TE, Ashley SW, Urman RD, Whang EE, Gold JS. The improvement in post-operative mortality following pancreaticoduodenectomy between 2006 and 2016 is associated with an improvement in the ability to rescue patients after major morbidity, not in the rate of major morbidity. 2020. PubMed
  • Saadat LV, Mahvi DA, Jolissaint JS, Urman RD, Gold JS, Whang EE. Discharge destination following rectal cancer resection: an analysis of preoperative and intraoperative factors. Int J Colorectal Dis 2019. PubMed
  • Reese SW, Ji E, Paciotti M, Leow JJ, Mahvi DA, Steele G, Urman RD, Whang EE, Kibel AS, Mossanen M. Risk factors and reasons for reoperation after radical cystectomy. Urol Oncol 2019. PubMed
  • Saadat LV, Mahvi DA, Jolissaint JS, Gabriel RA, Urman R, Gold JS, Whang EE. Twenty-Three-Hour-Stay Colectomy Without Increased Readmissions: An Analysis of 1905 Cases from the National Surgical Quality Improvement Program. World J Surg 2019. PubMed
  • Homsi J, Brovman EY, Rao N, Whang EE, Urman RD. The Association Between Potential Opioid-Related Adverse Drug Events and Outcomes in Colorectal Surgery. 2019. PubMed
  • Mahvi DA, Pak LM, Bose SK, Urman RD, Gold JS, Whang EE. Fast-Track Pancreaticoduodenectomy: Factors Associated with Early Discharge. World J Surg 2019; 43:1332-1341. PubMed
  • Mahvi DA, Pak LM, Urman RD, Gold JS, Whang EE. Discharge destination following pancreaticoduodenectomy: A NSQIP analysis of predictive factors and post-discharge outcomes. Am J Surg 2018. PubMed
  • Saadat LV, Fields AC, Lyu H, Urman RD, Whang EE, Goldberg J, Bleday R, Melnitchouk N. National Surgical Quality Improvement Program analysis of unplanned reoperation in patients undergoing low anterior resection or abdominoperineal resection for rectal cancer. Surgery 2018. PubMed
  • Lyu HG, Sharma G, Brovman EY, Ejiofor J, Urman RD, Gold JS, Whang EE. Unplanned reoperation after hepatectomy: an analysis of risk factors and outcomes. 2018. PubMed
  • Helander EM, Webb MP, Bias M, Whang EE, Kaye AD, Urman RD. A Comparison of Multimodal Analgesic Approaches in Institutional Enhanced Recovery After Surgery Protocols for Colorectal Surgery: Pharmacological Agents. 2017; 27:903-908. PubMed
  • Helander EM, Webb MP, Bias M, Whang EE, Kaye AD, Urman RD. Use of Regional Anesthesia Techniques: Analysis of Institutional Enhanced Recovery After Surgery Protocols for Colorectal Surgery. 2017; 27:898-902. PubMed
  • Whang EE, Stopfkuchen-Evans MF. Enhanced Recovery After Surgery: A New Standard for Perioperative Care. 2017; 27:859. PubMed
  • de Vos MS, Marang-van de Mheen PJ, Smith AD, Mou D, Whang EE, Hamming JF. Toward Best Practices for Surgical Morbidity and Mortality Conferences: A Mixed Methods Study. J Surg Educ 2017. PubMed
  • Najjar PA, Whang EE, Urman RD, McGrath CT, Beloff JR, Bleday R. Institution-wide Implementation Strategies, Finance, and Administration for Enhanced Recovery After Surgery Programs. Int Anesthesiol Clin 2017; 55:90-100. PubMed
  • Wu A, Brovman EY, Whang EE, Ehrenfeld JM, Urman RD. The Impact of Overestimations of Surgical Control Times Across Multiple Specialties on Medical Systems. J Med Syst 2016; 40:95. PubMed
  • Sutherland T, David-Kasdan JA, Beloff J, Mueller A, Whang EE, Bleday R, Urman RD. Patient and Provider-Identified Factors Contributing to Surgical Readmission After Colorectal Surgery. J Invest Surg 2016. PubMed
  • Shapiro M, Chen Q, Huang Q, Boosalis VA, Yoon CH, Saund MS, Whang EE, Gold JS. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. JAMA Surg 2015. PubMed
  • Sharma G, Whang EE, Ruan DT, Ito H. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. Ann Surg Oncol 2015. PubMed
  • Shapiro M, Rashid NU, Whang EE, Boosalis VA, Huang Q, Yoon C, Saund MS, Gold JS. Trends and predictors of resection of the primary tumor for patients with stage IV colorectal cancer. J Surg Oncol 2015; 111:911-6. PubMed
  • Shapiro M, Rashid NU, Huang Q, Galper SL, Boosalis VA, Whang EE, Gold JS. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States. JAMA Surg 2015; 150:274-7. PubMed
  • Gold JS, Al Natour RH, Saund MS, Yoon C, Sharma AM, Huang Q, Boosalis VA, Whang EE. Population-based outcome of stage IA-IIA resected gastric adenocarcinoma: who should get adjuvant treatment? Ann Surg Oncol 2013. PubMed
  • Lin CI, Whang EE, Lorch JH, Ruan DT. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery 2012; 152:1142-9. PubMed
  • Lin CI, Whang EE, Moalem J, Ruan DT. Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. Surgery 2012; 152:1045-50. PubMed
  • Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab 2011; 96:E554-65. PubMed
  • Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res 2010; 8:1217-26. PubMed
  • Cho NL, Lin CI, Whang EE, Carothers AM, Moore FD, Ruan DT. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. Thyroid 2010; 20:615-22. PubMed
  • Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE. Surgery and Staging of Pancreatic Neuroendocrine Tumors: A 14-Year Experience. J Gastrointest Surg 2010; 14:891-8. PubMed
  • Abramson MA, Pandharipande P, Ruan D, Gold JS, Whang EE. Radical resection for T1b gallbladder cancer: a decision analysis. 2009; 11:656-63. PubMed
  • Lin CI, Whang EE, Abramson MA, Jiang X, Price BD, Donner DB, Moore FD, Ruan DT. Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery 2009; 146:1208-14. PubMed
  • Lin CI, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD, Ruan DT. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 2009; 7:1655-62. PubMed
  • Lin CI,Whang EE,Abramson MA,Donner DB,Bertagnolli MM,Moore FD Jr,Ruan DT. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 2009; 379:626-31. PubMed
  • Abramson MA,Swanson EW,Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg 2009; 13:26-34. PubMed
  • Ito K,Ito H,Whang EE. Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines? J Gastrointest Surg 2008; 12:2164-70. PubMed
  • Irani JL,Ashley SW,Brooks DC,Osteen RT,Raut CP,Russell S,Swanson RS,Whang EE,Zinner MJ,Clancy TE. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J Gastrointest Surg 2008; 12:2177-82. PubMed
  • Irani JL,Cutler CS,Whang EE,Clancy TE,Russell S,Swanson RS,Ashley SW,Zinner MJ,Raut CP. Severe acute gastrointestinal graft-vs-host disease: an emerging surgical dilemma in contemporary cancer care. Arch Surg 2008; 143:1041-5; discussion 1046. PubMed
  • Rocha FG, Sundback CA, Krebs NJ, Leach JK, Mooney DJ, Ashley SW, Vacanti JP, Whang EE. The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine. Biomaterials 2008; 29:2884-90. PubMed
  • Ito K, Ito H, Tavakkolizadeh A, Whang EE. Is ductal evaluation always necessary before or during surgery for biliary pancreatitis? Am J Surg 2008; 195:463-6. PubMed
  • Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14:1470-7. PubMed
  • Ito K, Perez A, Ito H, Whang EE. Pancreatic pseudocysts: is delayed surgical intervention associated with adverse outcomes? J Gastrointest Surg 2007; 11:1317-21. PubMed
  • Liau SS, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Br J Cancer 2007; 96:993-1000. PubMed
  • Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006; 66:11613-22. PubMed
  • Liau SS, Ashley SW, Whang EE. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg 2006; 10:1254-62; discussion 1263. PubMed
Hide